every ‘to TRT or not’ thread I read treats the decision like a clean 2x2: symptoms present, levels below range, supplement or don’t. that framework works when hormones are the main variable you’re manipulating. it doesn’t transfer when you’re already on a GLP-1. here’s the actual comparison I’m running on myself: option A - add HRT now (estrogen +/- progesterone), give it 3-6 months, see what it does to hot flash frequency and glucose response option B - let tirzepatide stabilize for another 6-12 months, collect a clean baseline, then decide whether the remaining symptoms (4-6 hot flashes/week, 60% correlation with glucose spikes on my Libre 3) actually warrant hormonal intervention the attribution problem is the whole thing. my CRP went from 3.8 to 0.9 over 8 months on tirz. A1C from 9.1 to 5.7. those are exactly the markers HRT is supposed to help with - estrogen’s anti-inflammatory effect, insulin sensitization. if I add HRT now, I can’t separate the two signals on anything I track going forward. the TRT poster with T in the 550-750 range isn’t already on a drug touching the same hormonal axes. that’s the actual difference between his decision and mine. for now I’m at option B. but I need better hot flash severity tagging first - mild flush vs. drenching sweat are not the same cortisol event, and I’ve been treating them identically, which is a confound I need to close before I can even frame the HRT question cleanly.
The severity tagging instinct is the right one to chase first, and you’re correct that a mild flush and a drenching sweat aren’t the same event to be filing together. The piece I’d gently push on is the assumption that option B hands you a clean estradiol baseline at the end of it. If anyone ends up measuring your estradiol to frame the HRT question, ask what platform the lab actually runs, because standard immunoassay gets genuinely unreliable in the low perimenopausal range, the CV climbs ugly below roughly 30 pg/mL, which is exactly where your signal would sit. LC-MS/MS (often labelled sensitive estradiol) is the resolution that question needs, and most outpatient labs won’t reflex to it unless you ask your GP for it by name. So “collect a clean baseline” might land cleaner on the glucose and CRP side than on the hormone side, and that asymmetry is worth knowing before you commit a year to it. On the tagging itself, capturing severity in the moment rather than backfilling from memory at night is what made my own hunger logs less mushy. Logging it from the watch complication took enough friction out that I actually did it. Option B still reads like the sounder call from here.
LC-MS/MS by name is now in my GP notes. Perimenopausal estradiol variability within a single cycle can run 40-60%, which means one draw may not resolve the baseline problem regardless of platform. Sampling frequency is the other half of that equation
one variable that hasn’t come up yet: route of administration changes whether HRT even touches your CRP reading. oral estrogen first-passes the liver and bumps hepatic CRP synthesis, so a 0.9 could drift up purely as a synthesis artifact, not real inflammation coming back. transdermal mostly sidesteps that. same goes for triglycerides, oral estrogen raises them through the liver while transdermal is closer to neutral, so if you’re tracking trig:HDL as an insulin resistance proxy alongside the A1C, oral HRT corrupts that readout on top of the CRP one. that’s a second confounded channel stacked on the one you already named, and it’s route-dependent rather than HRT-vs-no-HRT, which i don’t see people separate. so option B isn’t just “wait for a clean baseline,” it might also be “if/when you add HRT, transdermal preserves more of your tracked markers as readable than oral does.” worth raising with whoever’s writing the script, since the metabolic-confound angle isn’t usually what drives the oral-vs-patch decision. on the severity tagging: i’d log the mild-flush vs drenching split as two separate tracked items from the start rather than one item with a severity number, because retro-coding a single stream is where i always lose the distinction. the free-text note tied to each entry is what saved me there, going back months later and actually seeing what the context was around a bad cluster instead of trusting a 1-10 i half-remember. 60% correlation with glucose spikes is a strong enough signal that i wouldn’t want it muddied by mixed event types either.
the hot flash severity tagging gap is actually where i’d start, bc it’s also the cleanest argument for option B. mild thermogenic flush vs. full drenching sweat likely have different cortisol and NE signatures, and lumping them inflates your “60% glucose correlation” number unpredictably. a study i read on menopausal hot flash phenotyping found the drenching subtype had significantly stronger sympathoadrenal activation than the mild flush type - which means they’re probably doing different things to your CGM trace, and you’d want that separated before you even calculate the HRT counterfactual. the attribution problem is real, but the underlying data quality problem gets there first.
The CRP arc you’ve described, 3.8 to 0.9 over eight months, is exactly why the attribution problem isn’t just methodological caution, it’s the whole frame. If you add estrogen now and inflammatory markers hold steady, you genuinely can’t tell whether tirz is still carrying that load or whether HRT picked up part of it. And that matters for future dose decisions in a way that can’t be reconstructed later. Where I’d gently push back is on the assumption that option B gives you a stable target to aim at. Perimenopause progression doesn’t pause while you’re optimizing your tracking protocol. Bone turnover, sleep architecture, cardiovascular risk markers, those are all moving on their own timeline regardless of what’s happening to ur A1C. A 12-month wait for a clean baseline might mean you’re adding HRT to a meaningfully different hormonal state than you have now, and that changes the interpretation just as much as the attribution problem you’re trying to avoid. The severity tagging is the piece I’d lock down first either way. I use the weekly trend summary in CareClinic to see hot flash frequency patterns against my fasting glucose numbers without manually parsing my spreadsheet every time, and even that relatively rough view makes the mild-flush vs. drenching-sweat distinction visible enough to start building a real tagging protocol. That distinction matters before you commit to either option.
the 60% correlation is doing a lot of work before you’ve split flush severity, so closing that confound first is the right order. one thing I’d add though: if you’re still cycling at all, tag cycle phase alongside severity. luteal (post-ovulation, estrogen falling) drives a different glucose pattern than the ovulation window, and people routinely mislabel the luteal hit as “mid-cycle.” that’s two axes, not one. fwiw the glucose-delta-tracks-severity idea should sharpen the model, not muddy it. if the drenching sweats cluster with your bigger spikes, that’s signal worth keeping separate.
the “clean baseline” in option B is the part I’d push on. the logic for waiting is sound, I’m not arguing the attribution problem away, adding HRT now genuinely means you can’t separate estrogen’s anti-inflammatory signal from tirz on CRP going forward. that’s real. but option B assumes the baseline you’re waiting 6-12 months for is stationary, and perimenopause isn’t. the estrogen decline is a curve, sometimes an accelerating one, so the “clean” physiology you collect at month 12 isn’t the same patient you are now. you might trade the tirz-vs-HRT confound for a where-am-I-on-the-perimenopause-curve confound and not realize you swapped one for the other. I’m running my own version of this and the moving-target problem is the thing I keep hitting. my CGM flagged a fasting-glucose drift before my endo named the perimenopause piece, and I genuinely can’t tell how much of what I’ve been attributing to tirz trough kinetics is sitting on top of an unaccounted hormonal slope underneath.
seven months of injection-day-vs-day-6 deltas and I still can’t cleanly subtract that out, because the denominator is shifting. on the hot flash severity tagging, that’s the right call and I’d go further: mild flush vs drenching sweat isn’t just a different cortisol event, the drenching ones fragment sleep, and broken sleep raises fasting glucose on its own. so your “60% correlation with glucose spikes” might be partly a sleep-disruption mechanism wearing a hot-flash costume. if the spikes cluster in the early fasting window rather than postprandially that’s a mild pointer toward the sleep path, not a clean answer, just a narrowing. none of this means add HRT now. it means “wait for a clean baseline” might be waiting for something perimenopause won’t hand you, and the better framing might be to log against the slope rather than hoping it flattens. ymmv, I’m earlier on this curve than I am on the tirz pharmacokinetics and I don’t have it resolved either.